Publications by authors named "Sarah Kavanagh"

Claim this Profile
B
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
Bruce Strober, Wolf-Henning Boehncke, James G Krueger, Nina Magnolo, Ronald Vender, Sarah Kavanagh

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.
Joseph F Merola, Richard B Warren, Diamant Thaçi, Kenneth B Gordon, Emi Nishida, Sarah Kavanagh

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial.
Andrew Blauvelt, Richard G Langley, Mark Lebwohl, Bruce Strober, Richard B Warren, Sarah Kavanagh

J Am Acad Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis.
Matthew C Baker, Sarah Kavanagh, Stanley Cohen, Alan K Matsumoto, Ara Dikranian

Arthritis Rheumatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
Richard S Finkel, Basil T Darras, Jerry R Mendell, John W Day, Nancy L Kuntz, Sarah Kavanagh

J Neuromuscul Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
Kevin A Strauss, Michelle A Farrar, Francesco Muntoni, Kayoko Saito, Jerry R Mendell, Sarah Kavanagh

Nat Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
Kevin A Strauss, Michelle A Farrar, Francesco Muntoni, Kayoko Saito, Jerry R Mendell, Sarah Kavanagh

Nat Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study.
Peter J Weiden, Alan Breier, Sarah Kavanagh, Andrew C Miller, Stephen K Brannan

J Clin Psychiatry· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial.
Nicholas Govsyeyev, Mark R Nehler, Cecilia C Low Wang, Sarah Kavanagh, William R Hiatt

J Vasc Surg· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y inhibitors: Insights from the EUCLID trial.
Judith Hsia, Sarah T Kavanagh, Charles W Hopley, Iris Baumgartner, Jeffrey S Berger

Vasc Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a pilot educational intervention on perceptions of visible skin diseases in the pediatric population.
Sneha Rangu, Katie Danielson, Sarah Schneider Kavanagh, Lisa Catanoso, Leanne Magee

J Am Acad Dermatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial.
William R Hiatt, Connie N Hess, Marc P Bonaca, Sarah Kavanagh, Manesh R Patel

Circ Cardiovasc Interv· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial.
Marat Fudim, Charles W Hopley, Zhen Huang, Sarah Kavanagh, Frank W Rockhold

Circ Cardiovasc Qual Outcomes· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From rote to reasoned: Examining the role of pedagogical reasoning in practice-based teacher education.
Sarah Schneider Kavanagh, Jenni Conrad, Sarah Dagogo-Jack

Teach Teach Educ· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease.
Axel Haine, Sarah Kavanagh, Jeffrey S Berger, Connie N Hess, Lars Norgren

J Am Coll Cardiol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teaching content in practice: Investigating rehearsals of social studies discussions.
Sarah Schneider Kavanagh, Chauncey Monte-Sano, Abby Reisman, Brad Fogo, Sarah McGrew

Teach Teach Educ· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.
Charles W Hopley, Sarah Kavanagh, Manesh R Patel, Cara Ostrom, Iris Baumgartner

Vasc Med· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Amit Bar-Or, Richard A Grove, Jerry M Tolson, Frederick J Derosier, Monica C Lopez, Sarah T Kavanagh

Neurology· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Amit Bar-Or, Richard A Grove, Daren J Austin, Jerry M Tolson, Susan A VanMeter, Sarah T Kavanagh

Neurology· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders.
R Norman Harden, Roy Freeman, Michelle Rainka, Lixin Zhang, Chris Bell, Sarah Kavanagh

Pain Med· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy.
Richard Rauck, Clare W Makumi, Sherwyn Schwartz, Ole Graff, Guy Meno-Tetang, Sarah T Kavanagh

Pain Pract· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The asymmetric synthesis of terminal aziridines by methylene transfer from sulfonium ylides to imines.
Sarah A Kavanagh, Alessandro Piccinini, Stephen J Connon

Org Biomol Chem· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748).
Lixin Zhang, Michelle Rainka, Roy Freeman, R Norman Harden, Christopher F Bell, Sarah Kavanagh

J Pain· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies.
Susan A VanMeter, Sarah T Kavanagh, Samantha Warren, Ronald W Barrett

CNS Drugs· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly enantioselective ylide-mediated synthesis of terminal epoxides.
Alessandro Piccinini, Sarah A Kavanagh, Stephen J Connon

Chem Commun (Camb)· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis